Table 1

miRNA expression in the CSF of patients with PCNSL versus control patients

Patients with PCNSL (n = 23)Control patients (n = 10)P†
Ct*SDCt*SD
miR-21 26.29 1.69 33.25 1.40 < .001 
miR-19b 28.76 2.85 33.01 2.84 < .001 
miR-92a 27.32 1.17 30.24 0.74 < .001 
miR-15b 32.98 1.31 34.80 1.46 .36 
miR-106b 32.85 1.45 31.31 5.71 .49 
miR-204 29.16 1.86 29.08 2.26 .62 
miR-24 31.21 1.09 31.18 1.00 .81 
Patients with PCNSL (n = 23)Control patients (n = 10)P†
Ct*SDCt*SD
miR-21 26.29 1.69 33.25 1.40 < .001 
miR-19b 28.76 2.85 33.01 2.84 < .001 
miR-92a 27.32 1.17 30.24 0.74 < .001 
miR-15b 32.98 1.31 34.80 1.46 .36 
miR-106b 32.85 1.45 31.31 5.71 .49 
miR-204 29.16 1.86 29.08 2.26 .62 
miR-24 31.21 1.09 31.18 1.00 .81 
*

Data are means of CT values (groupwise).

†

Comparison of miRNA expression among patients with PCNSL and control patients with neurologic disorders and was calculated with the Mann-Whitney U test.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal